Cape ANN Savings Bank boosted its position in shares of Abbott Laboratories (NYSE:ABT) by 0.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,421 shares of the healthcare product maker’s stock after buying an additional 15 shares during the period. Abbott Laboratories makes up approximately 1.3% of Cape ANN Savings Bank’s portfolio, making the stock its 26th largest position. Cape ANN Savings Bank’s holdings in Abbott Laboratories were worth $992,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of ABT. Whittier Trust Co. increased its position in shares of Abbott Laboratories by 1.7% in the first quarter. Whittier Trust Co. now owns 401,048 shares of the healthcare product maker’s stock worth $17,807,000 after buying an additional 6,751 shares in the last quarter. Marshwinds Advisory Co. increased its position in shares of Abbott Laboratories by 118.2% in the first quarter. Marshwinds Advisory Co. now owns 66,576 shares of the healthcare product maker’s stock worth $2,957,000 after buying an additional 36,069 shares in the last quarter. Farmers & Merchants Investments Inc. increased its position in shares of Abbott Laboratories by 7.6% in the first quarter. Farmers & Merchants Investments Inc. now owns 103,815 shares of the healthcare product maker’s stock worth $4,610,000 after buying an additional 7,309 shares in the last quarter. Miller Howard Investments Inc. NY increased its position in shares of Abbott Laboratories by 3.1% in the first quarter. Miller Howard Investments Inc. NY now owns 1,529,641 shares of the healthcare product maker’s stock worth $67,931,000 after buying an additional 46,118 shares in the last quarter. Finally, Reik & CO. LLC acquired a new position in shares of Abbott Laboratories during the first quarter worth $215,000. 70.98% of the stock is owned by institutional investors.

Abbott Laboratories (NYSE ABT) traded up 1.00% during trading on Friday, reaching $48.54. The company had a trading volume of 3,978,902 shares. Abbott Laboratories has a 52-week low of $37.38 and a 52-week high of $51.13. The company has a 50 day moving average price of $49.09 and a 200 day moving average price of $45.65. The company has a market capitalization of $84.34 billion, a PE ratio of 67.98 and a beta of 1.07.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.60 by $0.02. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The business had revenue of $6.64 billion for the quarter, compared to analyst estimates of $6.63 billion. During the same quarter last year, the firm earned $0.55 EPS. Abbott Laboratories’s revenue for the quarter was up 24.5% compared to the same quarter last year. On average, equities analysts forecast that Abbott Laboratories will post $2.49 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, August 15th. Investors of record on Friday, July 14th will be given a $0.265 dividend. This represents a $1.06 dividend on an annualized basis and a yield of 2.18%. The ex-dividend date is Wednesday, July 12th. Abbott Laboratories’s dividend payout ratio is presently 149.30%.

TRADEMARK VIOLATION NOTICE: This article was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/13/cape-ann-savings-bank-has-992000-position-in-abbott-laboratories-abt.html.

ABT has been the topic of a number of research reports. Stifel Nicolaus reiterated a “buy” rating and issued a $49.00 target price on shares of Abbott Laboratories in a report on Tuesday, April 18th. Jefferies Group LLC dropped their target price on Abbott Laboratories from $52.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, April 18th. UBS AG reiterated a “neutral” rating and issued a $41.00 target price on shares of Abbott Laboratories in a report on Tuesday, April 18th. Morgan Stanley reiterated an “equal weight” rating and issued a $42.00 target price on shares of Abbott Laboratories in a report on Wednesday, April 19th. Finally, Barclays PLC upped their target price on Abbott Laboratories from $50.00 to $52.00 and gave the company an “overweight” rating in a report on Thursday, April 20th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $52.08.

In related news, insider Stephen R. Fussell sold 196,550 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, June 8th. The stock was sold at an average price of $46.00, for a total value of $9,041,300.00. Following the sale, the insider now owns 221,488 shares of the company’s stock, valued at approximately $10,188,448. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Sharon J. Bracken sold 2,000 shares of Abbott Laboratories stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $49.16, for a total value of $98,320.00. Following the completion of the sale, the insider now directly owns 28,806 shares in the company, valued at approximately $1,416,102.96. The disclosure for this sale can be found here. In the last three months, insiders sold 218,702 shares of company stock worth $10,149,733. 0.76% of the stock is owned by insiders.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.